The hopes of precision medicine rely on our capacity to measure various high-throughput genomic information of a patient and to integrate them for personalized diagnosis and adapted treatment. Reaching these ambitious objectives...Read More
Design, Synthesis, Structure-Activity Relationship and Docking Studies of Novel Functionalized Arylvinyl-1,2,4-Trioxanes as Potent Antiplasmodial as well as Anticancer Agents.
A novel series of functionalized synthetic substituted arylvinyl-1,2,4-trioxanes ( 8a-p ) has been prepared and assessed for in vitro antiplasmodial activity against chloroquine-resistant Pf INDO strain of Plasmodium falciparum...Read More
Detection of circulating natural antibodies against CD25, MUC1 and VEGFR1 for early diagnosis of non-small cell lung cancer.
We previously demonstrated that a deficiency of natural antibodies against CD25, Mucin 1 (MUC1) and vascular endothelial growth factor receptor 1 (VEGFR1) could contribute to high risk of non-small cell lung cancer (NSCLC). This...Read More
The role of surgery for small cell lung cancer (SCLC) is not clear. We aimed to evaluate this issue using a population-based database.Patients diagnosed between 2004 and 2014 with SCLC staged T1-4 N0-2 M0 disease were retrieved...Read More
Posted by Physicians Weekly | May 11, 2020
Source: Practice recommendations for lung cancer radiotherapy during COVID-19 pandemic: An...Read More
Posted by PWeekly | May 1, 2020
Evidence suggests that, despite increased public health efforts to discourage teens from using hazardous tobacco products, use of electronic nicotine delivery systems (ENDS) remains high, due in part to direct youth targeting by...Read More
Diplatin, a novel water-soluble platinum complex, inhibits lung cancer growth via augmentation of Fas-mediated apoptosis.
Platinum drugs, such as cisplatin (DDP) and carboplatin (CBP), are the main drugs for the treatment of lung cancer, but their practical clinical application is limited by severe toxicity and acquired drug resistance. Our...Read More
Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial.
Preserving health related quality of life (HRQOL) plays an important role in considering stereotactic body fractionated radiotherapy (SBRT). The prospective monocenter phase II STRIPE trial investigated long-term HRQOL after...Read More
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
The formation of an immunosuppressive microenvironment and up-regulation of PD-L1 protein are the main causes of tumor immune escape. Previous reports suggest that Angiotensin II (Ang II) can modulate the immune status of tumor...Read More